Bartolome Celli
Pulmonary Disease · Boston, MANPI 1699762773
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $447,425 of the $536,200 with a category attached, or 83.4%. 19 manufacturers reported payments, led by AstraZeneca at 29.9% of the total. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $2224.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$160K
- GSK$151K
- Sanofi US Services Inc.$52K
- Chiesi USA, Inc.$51K
- Sanofi$25K
- Astrazeneca UK Limited$25K
- plus $71K from 13 others
Across 11 payments — averaging $1773.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$11K
- Chiesi USA, Inc.$7K
- Sanofi$1K
What the payments were for
- Consulting fees$447,42583%
- Speaking & faculty fees$77,72014%
- Travel & lodging$8,7752%
- Food & beverage$2,2490%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 74 | $160,308 |
| GSK | 85 | $151,455 |
| Sanofi US Services Inc. | 14 | $52,299 |
| Chiesi USA, Inc. | 10 | $51,167 |
| Sanofi | 4 | $25,032 |
| Astrazeneca UK Limited | 11 | $24,713 |
| Astrazeneca AB | 9 | $17,776 |
| F. Hoffmann-la Roche AG | 12 | $12,634 |
| Sanofi-aventis U.S. LLC | 4 | $12,048 |
| Verona Pharma, Inc. | 2 | $6,512 |
| Boehringer Ingelheim | 2 | $5,253 |
| Gilead | 1 | $5,180 |
| Regeneron | 6 | $4,890 |
| Pulmonx Corporation | 2 | $2,875 |
| Aero US Inc | 1 | $2,706 |
| Viiv Healthcare Company | 1 | $600 |
| Boehringer Ingelheim International GmbH | 1 | $564 |
| Medical Graphics Corporation | 1 | $161 |
| Insmed, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$72,737
- TRELEGY ELLIPTA$58,343
- DUPIXENT$39,561
- BREZTRI$28,083
- NO PRODUCT DISCUSSED$19,859
- BREZTRI AEROSPHERE$19,222
- Ohtuvayre$6,512
- AEROGEN SOLO NEBULIZER SYSTEM$5,412
- TEZSPIRE$4,727
- SPIRIVA$3,438
- AEROGEN USB CONTROLLER SYSTEM$2,706
- AEROGEN SOLO; AEROGEN ULTRA$2,706
- STIOLTO RESPIMAT$2,379
- Pulmonx Endobronchial Valve EBV$2,275
- NUCALA$975
- CHARTIS CATHETER$600
- ZEPHYR ENDOBRONCHIAL VALVE$600
- ZEPHYR DELIVERY CATHETER$600
- PULMONX CHARTIS TABLET CONSOLE$600
How this compares
$536,200 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.